热门出版物 - 学术资源搜索

h5 指数:61
h5 中位数:108

h5 指数是指在过去整整 5 年中所发表文章的 h 指数。h 指在 2018-2022 年间发表的 h 篇文章每篇至少都被引用过 h 次的最大值。隐藏

出版物的 h5 中位数，是指出版物的 h5 指数所涵盖的所有文章获得的引用次数的中位值。隐藏

#7 Rheumatology

标题/作者	引用次数	年份
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study G Cavalli, G De Luca, C Campochiaro, E Della-Torre, M Ripa, D Canetti, ... The Lancet Rheumatology 2 (6), e325-e331	988	2020
Tocilizumab in patients with severe COVID-19: a retrospective cohort study G Guaraldi, M Meschiari, A Cozzi-Lepri, J Milic, R Tonelli, M Menozzi, ... The Lancet Rheumatology 2 (8), e474-e484	972	2020
Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia D McGonagle, JS O'Donnell, K Sharif, P Emery, C Bridgewood The Lancet Rheumatology 2 (7), e437-e445	829	2020
Anakinra for severe forms of COVID-19: a cohort study T Huet, H Beaussier, O Voisin, S Jouveshomme, G Dauriat, I Lazareth, ... The Lancet Rheumatology 2 (7), e393-e400	625	2020
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study N Biran, A Ip, J Ahn, RC Go, S Wang, S Mathura, BA Sinclaire, U Bednarz, ... The Lancet Rheumatology 2 (10), e603-e612	299	2020
Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study BJ Webb, ID Peltan, P Jensen, D Hoda, B Hunter, A Silver, N Starr, ... The Lancet Rheumatology 2 (12), e754-e763	272	2020
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial RA Furie, EF Morand, IN Bruce, S Manzi, KC Kalunian, EM Vital, TL Ford, ... The Lancet Rheumatology 1 (4), e208-e219	268	2019
The immunology of COVID-19: is immune modulation an option for treatment? J Zhong, J Tang, C Ye, L Dong The Lancet Rheumatology 2 (7), e428-e436	250	2020
COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study JJ Manson, C Crooks, M Naja, A Ledlie, B Goulden, T Liddle, E Khan, ... The Lancet Rheumatology 2 (10), e594-e602	235	2020
Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries MA Gianfrancesco, KL Hyrich, L Gossec, A Strangfeld, L Carmona, ... The Lancet Rheumatology 2 (5), e250-e253	228	2020
Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome P Mehta, RQ Cron, J Hartwell, JJ Manson, RS Tattersall The Lancet Rheumatology 2 (6), e358-e367	217	2020
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study G De Luca, G Cavalli, C Campochiaro, E Della-Torre, P Angelillo, ... The Lancet Rheumatology 2 (8), e465-e473	214	2020
The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements AM Hoffmann-Vold, TM Maher, EE Philpot, A Ashrafzadeh, R Barake, ... The Lancet Rheumatology 2 (2), e71-e83	201	2020
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study J Avouac, E Drumez, E Hachulla, R Seror, S Georgin-Lavialle, ... The Lancet Rheumatology 3 (6), e419-e426	197	2021
Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study MB Moor, F Suter-Riniker, MP Horn, D Aeberli, J Amsler, B Möller, ... The Lancet Rheumatology 3 (11), e789-e797	165	2021
Central sensitisation in chronic pain conditions: latest discoveries and their potential for precision medicine J Nijs, SZ George, DJ Clauw, C Fernández-de-las-Peñas, E Kosek, ... The Lancet Rheumatology 3 (5), e383-e392	165	2021
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial APJ Vlaar, S de Bruin, M Busch, SA Timmermans, IE van Zeggeren, ... The Lancet Rheumatology 2 (12), e764-e773	157	2020
COVACTA trial raises questions about tocilizumab's benefit in COVID-19 B Furlow The Lancet Rheumatology 2 (10), e592	150	2020
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study G Cavalli, A Larcher, A Tomelleri, C Campochiaro, E Della-Torre, ... The Lancet Rheumatology 3 (4), e253-e261	149	2021
COVID-19 vasculitis and novel vasculitis mimics D McGonagle, C Bridgewood, AV Ramanan, JFM Meaney, A Watad The Lancet Rheumatology 3 (3), e224-e233	148	2021

1 - 20

计算机程序会自动估算并确定日期和引用次数。